Murchinson’s Briacell Therapeutics BCTX Stock Holding History

Murchinson’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,667	Closed	-$1.33M	–	109
2021 Q2	$1.33M	Buy	+1,667	New	+$1.04M	0.48%	41

Other funds holding BCTX

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

STA

Summit Trail Advisors New York $7.95B AUM 26.49% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $359M AUM 23.01% 1-Year Est. Return

Belvedere Trading Chicago, Illinois $87.6B AUM 131.08% 1-Year Est. Return

Murchinson's BCTX Position: Q3 2021 in Review

Murchinson sold out of Briacell Therapeutics (BCTX) in Q3 2021, closing a stake of 1,667 shares — an estimated $1.33M sold.

Murchinson first reported a position in BCTX in Q2 2021 and held it in 1 quarter. The position peaked at $1.33M in Q2 2021. 19 funds tracked by Wall St. Rank hold BCTX as of Q3 2021.

Murchinson reported no remaining Briacell Therapeutics position as of Q3 2021 after selling out during the quarter.
Murchinson sold 1,667 Briacell Therapeutics shares in Q3 2021, an estimated $1.33M.
Murchinson first reported a position in Briacell Therapeutics in Q2 2021 and held it in 1 quarter.
Murchinson's Briacell Therapeutics position peaked at $1.33M in Q2 2021.
19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q3 2021.

Based on Murchinson's 13F filing for Q3 2021, filed 15 Nov 2021.